SWITZERLAND - Sofinnova Ventures leads CHF 36m funding for PregLem SA

San Francisco-based Sofinnova Ventures has led a series-B funding round for Swiss company PregLem SA. Sofinnova has already provided seed capital and acted as lead investor in the series-A round. MVM Life Science Partners LLP, based in London, and NeoMed Management, based in Geneva, invested in the round. The new capital will be used to develop a molecule licensed-in from privately-held French company, HRA Pharma, for the pre-operative treatment of uterine myoma. PregLem has raised CHF 68 million in less than one year.